Fig. 1

MeRIP-seq reveals correlation between m6A and cell adhesion, and ALKBH5 is associated with GC prognosis (A) M6A level of mRNA from 5 pairs of clinical tumor tissues with adjacent normal samples. (B) Peak distribution of m6A modification in meRIP-seq results. (C) The sequence motif identified from sequencing profile. (D) Volcano plot of m6A peaks detected by meRIP-seq in normal tissues (NT) and GC tissues. Red dots mean m6A peaks high in GC, while blue dots mean m6A peaks high in NT. Note that multiple peaks may map to the same gene. (E) GO analysis of genes with high m6A level in GC. (F) Volcano plot of mRNA level detected by meRIP-seq between NT and GC tissues. Red dots mean high expression of mRNA in GC, while blue dots mean high mRNA expression in NT. (G) Correlation analysis between metastatic-associated genes and m6A “eraser” in TCGA database. Blue means positive correlation (p < 0.05) and orange means negative correlation (p < 0.05). Grey means no significance (p > 0.05). (H-J) MRNA expression comparison of ALKBH5 between tumor and normal tissues among cohort2, TCGA database and GEO dataset. (K-L) Representative IHC pictures of ALKBH5 in GC tissue microarray (TMA) and the comparison of area density in ALKBH5-staining (scale bars = 100 µm). (M) The receiver operating characteristic (ROC) analysis of ALKBH5 expression in TMA. (N) Survival analysis of ALKBH5 expression in GC patients (p < 0.0001, log-rank test). (O-P) Expression comparison of ALKBH5 between metastasis-/ + and limph nodes metastasis-/ + group in TCGA dataset and TMA